Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Y-mAbs Therapeutics Inc.

www.ymabs.com

Latest From Y-mAbs Therapeutics Inc.

Keeping Track, Oncology Edition: Biologic Breakthroughs And BLAs

The latest oncology development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Cancer

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September

The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.

Financing Business Strategies

Priority Reviews At US FDA: From Third Quarter Spikes To A Third Quarter Trough

Priority review announcements saw significant dip in third quarter 2018, while they usually experience a spike during the period; breakthrough therapy designations remained in double digits.
Review Pathway Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Y-mAbs Therapeutics Inc.
  • Senior Management
  • Claus Moller, MD, PhD, CEO
    Bo Kruse, CFO
    Thomas Gad, Pres. & Head, Bus. Dev. & Strategy
    Steen Lisby, MD, SVP, CMO
    Joris Wilms, SVP, COO
  • Contact Info
  • Y-mAbs Therapeutics Inc.
    Phone: (212) 847-9841
    230 Park Ave.
    Ste. 3350
    New York, NY 10169
    USA
UsernamePublicRestriction

Register